I stand corrected - there is a November report with a $17.50 target. There was also a general biotech report issued in January with a $31.00 PT. Rather than writing inane comments, why don't you, as I did, do some investigation.
I stand corrected. While the individual report on INSM in November had a $17.50 price target, the analyst, Matthew Roden, on January 6, 2014 issued a 36 page report on US Biotechnology. In that report, he reiterated his Buy for INSM and increased his price target to #31.00. I apologize for my earlier post.
I just spoke with a friend at UBS. In contrast to terry_insm's statement, UBS has not changed their Buy rating on the stock with a price target of $17.50. Unless terry_insm has insider information related to UBS, I can definitively state that as of 10 minutes ago there has been no change.